Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Big Pharma-backed GlycoEra raises $130M for protein degraders
The cash will primarily go toward initiating clinical trials for GE8820, a bispecific molecule designed to destroy IgG4 autoantibodies.
Darren Incorvaia
May 27, 2025 7:00am
Octagon shuts down after R&D challenges put it behind the 8 ball
Apr 29, 2025 7:40am
Genentech builds autoimmune Repertoire with $765M deal
Apr 23, 2025 7:00am
Immunovant narrows R&D focus as Roivant execs join C-suite
Apr 21, 2025 10:00am
Boehringer lines up B-cell depletion autoimmune R&D via Cue deal
Apr 15, 2025 4:45am
J&J links FcRn blocker to sustained benefits as FDA ruling nears
Apr 8, 2025 10:21am
